Finanzen von Neurosense Therapeutics Ltd (NRSN)NRSNNeurosense Therapeutics Ltd

Evaluating the bottom line, Neurosense Therapeutics Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -2174.98%, provide a clear picture of how effectively NRSN converts its operational activities into shareholder value.

In the context of the broader market, NRSN competes directly with industry leaders such as PBM and AEON. With a market capitalization of $16.58M, it holds a leading position in the sector. When comparing efficiency, NRSN's gross margin of N/A stands against PBM's N/A and AEON's N/A. Such benchmarking helps identify whether Neurosense Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

The company reported a GAAP EPS of -0.11 for Q3 2024, indicating continued financial strain. Its current ratio is low at 0.21, suggesting liquidity issues.